Mineralys Therapeutics first drew attention in 2021 with a bold bet on a new type of hypertension drug. It came with a $1 million upfront fee to the medicine's originator, Tanabe Pharma.
Jon Congleton, Mineralys Therapeutics CEO
June 3, 2026 10:32 AM EDT
Financing
Mineralys makes money moves before looming hypertension approval
Kyle LaHucik
NewLimit’s $435M megaround; Lilly’s busy dealmaking week
Lobe Sciences Announces Proposed Shares for Debt Transaction
City banks nearly $100M for next-gen RNAi drugs
Axsome fends off generic competition to narcolepsy med Sunosi until 2040
CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment
Advanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment
Study data convince Lundbeck to push new migraine drug forward
MindMaze Therapeutics Announces Non-Core Asset Sale and Organizational Simplification
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
Legend Biotech emerged as a rare market winner
Cytokinetics executives said their first FDA-approved drug is off to a strong start as it goes up against its Bristol Myers…
The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere,…
Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's…
One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA,…
Apogee Therapeutics secures up to $800 million royalty deal with Blackstone Life Sciences to fund Phase 3 trials of eczema drug…
A Cytokinetics heart disease drug — already approved in one indication — succeeded in another Phase 3 trial, a potential boost…
